Literature DB >> 16397128

Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

Elena Gonzalez-Rey1, Alejo Chorny, Amelia Fernandez-Martin, Doina Ganea, Mario Delgado.   

Abstract

Induction of antigen-specific tolerance is critical for autoimmunity prevention and immune tolerance maintenance. In addition to their classical role as sentinels of the immune response, dendritic cells (DCs) play important roles in maintaining peripheral tolerance through the induction/activation of regulatory T (T(reg)) cells. The possibility of generating tolerogenic DCs opens new therapeutic perspectives in autoimmune/inflammatory diseases. Characterizing endogenous factors that contribute to the development of tolerogenic DCs is highly relevant. We here report that the immunosuppressive neuropeptide vasoactive intestinal peptide (VIP) induces the generation of human tolerogenic DCs with the capacity to generate CD4 and CD8 T(reg) cells from their respective naive subsets. The presence of VIP during the early stages of DC differentiation from blood monocytes generates a population of IL-10-producing DCs unable to fully mature after the effects of inflammatory stimuli. CD4 T(reg) cells generated with VIP-differentiated DCs resemble the previously described Tr1 cells in terms of phenotype and cytokine profile. CD8 T(reg) cells generated with tolerogenic VIP DCs have increased numbers of IL-10-producing CD8(+)CD28(-)-CTLA4(+) T cells. CD4 and CD8 T(reg) cells primarily suppress antigen-specific T(H)1-mediated responses. Therefore, the possibility of generating or expanding ex vivo tolerogenic DC(VIPs) opens new therapeutic perspectives for treating autoimmune diseases and graft-versus-host disease after allogeneic transplantation in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397128      PMCID: PMC1895772          DOI: 10.1182/blood-2005-11-4497

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  CD8(+)CD28(-) T suppressor cells represent a distinct subset in a heterogeneous population.

Authors:  A I Colovai; R Ciubotariu; Z Liu; R Cortesini; N Suciu-Foca
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

Review 2.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity.

Authors:  Arno Hänninen; Nathan R Martinez; Gayle M Davey; William R Heath; Leonard C Harrison
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection.

Authors:  J X Gao; J Madrenas; W Zeng; M J Cameron; Z Zhang; J J Wang; R Zhong; D Grant
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 5.  The role of CD40 in peripheral T cell tolerance and immunity.

Authors:  L Diehl; A T Den Boer; E I van der Voort; C J Melief; R Offringa; R E Toes
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

6.  Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.

Authors:  Madhav V Dhodapkar; Ralph M Steinman
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

7.  Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.

Authors:  H Jonuleit; E Schmitt; G Schuler; J Knop; A H Enk
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 8.  Differentiation of T regulatory cells by immature dendritic cells.

Authors:  M G Roncarolo; M K Levings; C Traversari
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

9.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

Authors:  T Takahashi; T Tagami; S Yamazaki; T Uede; J Shimizu; N Sakaguchi; T W Mak; S Sakaguchi
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

View more
  56 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

3.  Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease.

Authors:  Ashley D Reynolds; David K Stone; Jessica A L Hutter; Eric J Benner; R Lee Mosley; Howard E Gendelman
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

Review 4.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

Review 5.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

6.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 7.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

8.  Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients.

Authors:  Jian-Ming Li; Mohammad S Hossain; Lauren Southerland; Edmund K Waller
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 9.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 10.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.